In the mid-1990s he theorized that CTLA-4 might prevent the immune system from mounting an effective response against tumors.

FORBES: Targeting Melanoma

But Glaxo says Cervarix uses a more powerful technology to spur a response from the immune system--potentially making Cervarix more effective.

FORBES: Glaxo Goes Head-To-Head With Merck